MyChart is not for medical emergencies. If you have a medical emergency, call 911.
If you need help with MyChart, call us at 1-844-442-4278
In the past few decades, tremendous strides have been made in the treatment of adult lymphomas — a group of blood cancers that begin in the white blood cells. Personalized and targeted therapies are resulting in higher success rates and patients surviving and thriving. Ongoing progress continues to offer hope and healing for patients facing this disease.
The University of Chicago Medicine has been at the forefront of this great move forward in lymphoma care. Here, the brightest minds in medicine work every day to advance the care of patients with lymphoma. Our lymphoma experts are committed to developing new therapies for this complex disease and bringing the latest treatments to our patients as quickly as possible. As one of the busiest lymphoma programs in Chicago, we manage care for thousands of patients and see approximately 250 new cases each year.
Our hematopathologists (physician-scientists who analyze blood samples and tissue) have extensive knowledge and expertise in identifying lymphoma and accurately pinpointing its different subtypes — some of which are particularly difficult to diagnose. Physicians from around the world regularly consult with our hematopathologists on complicated lymphoma cases.
We take an aggressive approach to treating lymphomas that return after initial treatment. In some cases, stem cell transplantation offers the best chance to cure patients with relapsed lymphoma.
We were the first medical center in Illinois to offer CAR T-cell therapy, a breakthrough immunotherapy for the treatment of certain types of non-Hodgkin lymphoma and leukemia. CAR T-cell therapy supercharges the patient’s disease-fighting T-cells to find and destroy cancer cells.
Lymphomas (Hodgkin and non-Hodgkin) are the third most common cancer in adolescents and young adults. The Adolescent and Young Adult (AYA) Oncology Program at UChicago Medicine addresses the unique needs of this age group.
We offer long-term follow-up and care for adults who were treated for lymphoma as adolescents or young adults. Patients receive an individualized survivorship plan to help them address any medical or psychosocial issues they experience as a result of cancer or its treatment.
The Hoogland Lymphoma Biobank at UChicago Medicine is an innovative new program that links epidemiology (the study of how disease spreads and can be controlled) to malignant lymphoma tissue. The biobank collects and stores donated biospecimens (e.g. tissue, urine, blood) and connects it to personal and medical information. Biobank researchers will examine how lifestyle, occupation, environment and genes affect lymphoma. The goal of the program is to increase understanding of how to prevent, diagnose and treat lymphoma.
CAR T-cell therapy supercharges a patient's white blood cells to seek out and destroy cancer cells. Research at UChicago Medicine played a key role in the development of this exciting new immunotherapy.View videos and learn more